| abstract |
The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors of Formula I: n nor pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1. |